Thanks to the participation of social impact investors, the company can continue to focus their therapies on pediatrics
The product, Zelium, is a therapeutic alternative for treating a serious complication in diabetic patients
Caixa Capital Risc and Kereon Partners have invested in this spin-off created through technology transfer from IDIBAPS-Hospital Clínic de Barcelona
The biotech firm has opened a crowdequity round of funding on the Capital Cell platform and has created a campaign on social media
The agreement also includes a purchase option on the remaining 51%, which the Catalan multinational corporation may exercise in 2022
The firm has published a study with the University of the Basque Country and IRB Barcelona and is beginning the preclinical regulatory phase for the candidate
The biotech firm has launched a crowd-funding campaign through Capital Cell to complete the preclinical phase and begin trials in humans
The deal will accelerate development of a new antibody to fight cancer
The two companies will be present in 25 countries and together will have the largest database of healthcare professionals in the world
ACCIÓ is organising a mission to Shanghai and Hong Kong for businesses and institutions in collaboration with Biocat, Fenin and Health Tech Cluster
